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Summary 
Polycystic ovarian syndrome (PCOS) is a heterogenous disorder associated with clinical, 
endocrine and ultrasonographic features that can also be encountered in a number of other 
diseases. It has traditionally been suggested that prolactin excess, enzymatic steroidogenic 
abnormalities and thyroid disorders need to be excluded before a diagnosis of PCOS is 
made. However, there is paucity of data regarding the prevalence of PCOS-phenotype in 
some of these disorders, whereas other endocrine diseases that exhibit PCOS-like features 
may elude diagnosis and proper management if not considered. The present article reviews 
the data of currently included entities that exhibit a PCOS-phenotype and those that 
potentially need to be looked for, and attempts to identify specific features that distinguish 
them from idiopathic PCOS.     
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Introduction 
Clinical and/or biochemical hyperandrogenism and menstrual irregularity are the most 
common complaints for which premenopausal women seek endocrine consultations1. The 
great majority of such women will be found to have Polycystic Ovarian Syndrome (PCOS) 
that is associated with a distinct ultrasonographic polycystic ovarian (PCO) appearance1,2. 
Although the aetiology of PCOS has not been delineated, it is considered to represent a 
functional hyperandrogenic state of ovarian and/or adrenal origin with or without 
associated insulin resistance2. However, the clinical, endocrine and morphological 
characteristics of PCOS can also be encountered in a number of other conditions of specific 
etiology3-6. It has therefore been suggested that the diagnosis of PCOS should be made 
when other conditions that could present with a similar clinical/biochemical/morphological 
phenotype, namely thyroid disorders, states of prolactin excess and congenital adrenal 
hyperplasia, are excluded4,5,6 (Table 1). However, the existence of precise indications and 
extent of investigations that needs to be undertaken to exclude the presence of such 
disorders, along with others that may also exert a similar phenotype, have not been clearly 
defined3. In contrast to PCOS, some of these latter conditions can be life threatening or 
associated with increased morbidity if left undiagnosed3. It is therefore important to be 
aware of all these disorders and recognize any particular features that distinguish them 
from idiopathic PCOS.  
 
Steroidogenic pathway and cortisol biosynthesis deficiencies 
Although the manifestations of classic (complete enzymatic defect) congenital adrenal 
hyperplasia (CAH) are evident from birth, the non-classic (mild enzymatic defect) form 
becomes apparent in adolescence or later (late-onset CAH)7. The prevalence of late-onset 
CAH ranges between 1-10%, depending on ethnicity, with late onset 21-hydroxylase (OH) 
deficiency being the most common cause (1:500-1000 in various Caucasian populations)7. 
In cases of CAH, ACTH levels increase to overcome the block in cortisol biosynthesis leading 
to increased androgen secretion and the development of symptoms/signs similar to those of 
patients with PCOS7,8. Early initial studies have shown that ultrasonographically detected 
PCO were found in 83% of adult patients, 40% of post-pubertal and 3% of pre- and peri-
pubertal girls with late-onset CAH9. In view of these findings it was suggested that 
measurement of early follicular 17-hydroxyprogesterone (17OH-PG) levels, followed by an 
ACTH-stimulation test in cases with borderline values, is required to distinguish between 
these two conditions8. In an attempt to identify clinical and other features that distinguish 
PCOS from late onset-CAH subsequent comparative studies showed that patients with CAH 
were less likely to demonstrate anovulation than patients with PCOS10. In addition, PCO 
were found in only 24% of CAH compared to approximately 90% of patients with PCOS, 
whereas maximum ovarian volume and follicle counts, albeit increased in both groups 
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compared to controls, were significantly higher in PCOS patients (10.2 vs. 6.1 ml and 11.7 vs. 
8.1, respectively)10. As expected 17OH-PG levels were increased in the great majority of CAH 
patients, whereas an LH:FSH ratio of >2 was found mostly in patients with PCOS. However, 
besides the presence of some features that may help distinguishing these two conditions, 
the gold standard in cases of doubt remains the 17-OH-PG response to ACTH stimulation8,9. 
Moreover, urine steroid metabolomics (Gas chromatography/mass spectrometry-GC/MS) 
has been shown to be a novel, non-invasive, highly sensitive, and specific biomarker tool 
for the diagnosis of defects in steroidogenesis7. Pregnanetriol, 17-OH pregnanolone and 
pregnanetriolone are considered to be the urinary metabolites typically increased in cases 
of 21-OH deficiency7. Patients with late-onset CAH also exhibit metabolic abnormalities and 
insulin resistance (IR) similar to lean PCOS further enhancing adrenal and ovarian androgen 
production3,8. Although symptomatic treatment of these two conditions may be similar 
including the administration of anti-androgens and contraceptives, application of etiological 
treatment in CAH patients may require the administration of glucocorticoids8,9.    
 
States of prolactin excess 
Approximately 20% of women with PCOS have elevated prolactin levels suggesting that 
hyperprolactinaemia may reflect an abnormal ovarian response to an altered gonadotrophin 
drive11. In addition, a number of mainly retrospective studies have revealed a 56% and 50-
67% prevalence of hirsutism and PCO in hyperprolactinaemic patients, respectively, 
whereas testosterone levels were found to be higher in hyperprolactinaemic patients with 
PCO compared to those without PCO11,12. Previous studies have attempted to characterize 
such patients according to their hormonal response to TRH, GnRH, and metoclopramide, 
suggesting that hyperprolactinaemia in patients with PCOS may be the result of the 
abnormal hormonal milieu with or without associated dopamine deficiency leading to 
anovulatory cycles12. As prolactin receptor expression has been documented in the 
adrenals, it has also been suggested that hyperprolactinaemia could augment adrenal 
androgen secretion3,13. However, there is a lack of well conducted prospective studies 
evaluating the prevalence of PCO/PCOS and identification of possible underlying 
mechanisms in women with different causes of hyperprolactinaemia, and thus the 
association between prolactin excess and PCOS might not be causal, but rather an integral 
part of PCOS. 
 
Thyroid disorders 
Increase in ovarian volume and presence of ovarian cystic changes have been reported in 
patients with primary hypothyroidism (PH), whereas thyroid disorders and autoimmunity 
are more common in women with PCOS14. Although the underlying mechanism has not 
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been delineated it is hypothesized that increased prolactin secretion, that accompanies PH, 
affects gonadotrophin secretory pattern and promotes adrenal androgen secretion14. In 
addition, increased TSH levels may increase collagen deposition and overall ovarian volume. 
In a study of 26 patients with PH and mean TSH levels of 57.1 mU/L, ovarian volumes were 
larger than controls and a number of patients acquired multiple ovarian cysts that all 
reverted to normal following thyroxine replacement therapy15. In addition, decreased sex 
hormone binding globulin (SHBG) and increased free testosterone levels were found in 
hypothyroid patients, whereas increased SHBG and dehydroepiandrosterone sulfate (DHEA-
S) levels have been described in hyperthyroid patients16. However, there are no convincing 
data derived from large scale studies demonstrating a direct relation of thyroid dysfunction 
or association of thyroid autoimmunity with PCOS.     
 
More recent evidence suggests that a number of other conditions may also present with a 
PCOS-phenotype. It is therefore important to familiarize with the presence of such disorders 
as early presentation may not always be typical of overt disease raising 
clinical/endocrinological suspicion. 
 
Cushing’s syndrome (CS) 
A significant number of patients with CS develop hirsutism and approximately 70-80% 
menstrual abnormalities, besides the absence of raised androgen levels17,18. As all patients 
with CS have low SHBG levels, as a result of cortisol induced IR and hyperinsulinemia, the 
free androgen index is increased leading to hirsutism18. PCO are found in 46% of patients 
with CS; in addition, there is a strong negative correlation between menstrual pattern and 
gonadotrophins with cortisol levels17. Thus, it has been suggested that when cortisol levels 
are moderately raised, gonadotrophin stimulation to the ovaries is maintained leading to an 
estrogen sufficient PCOS-like phenotype, whereas highly elevated cortisol levels lead to a 
hypogonadotropic hypogonadism state17,3. In such cases, hyperinsulinemia may act as a co-
gonadotropin stimulating the ovaries, thus maintaining ovarian steroid output and leading 
to the development of PCO17,3. This hypothesis is supported further by reports of patients 
with early or mild CS being misdiagnosed as PCOS19. 
 
Acromegaly 
Between 40-80% of patients with acromegaly develop hirsutism and menstrual 
irregularity20. The majority of patients with large pituitary tumours are associated with 
complete or partial gonadotrophin deficiency, with or without concomitant 
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hyperprolactinemia, leading to a hypogonadotrophic hypogonadal state20. However, 
acromegalic patients presenting with a PCOS-like phenotype exhibiting an exaggerated LH 
response to LHRH have also been described20,3. Such patients usually have pituitary 
microadenomas and maintain an estrogen sufficient milieu20,3. Although the majority of 
patients with acromegaly do not have high androgen levels, they exhibit low SHBG levels 
that correlate inversely with GH levels, a finding that could explain the presence of hirsutism 
despite normal androgen levels20. A recent prospective study evaluating 14 pre-menopausal 
patients with active acromegaly showed that 50% had PCO and 45% fulfilled the criteria of 
PCOS21. Women with PCOS had increased mean ovarian volumes and characteristic 
morphology compared to those without, higher IGF-1 and testosterone levels and lower 
SHBG levels21. It is prudent to suggest that GH/IGF-1 excess or IR can affect steroid 
production, SHBG levels and ovarian function, and induce a PCOS-phenotype even in a 
gonadotrophin deficient state21. 
 
Adrenal and ovarian androgen secreting tumours 
Androgen-secreting neoplasms, mostly arising from the adrenals or ovaries, are relatively 
rare and potentially life-threatening and may be associated with virilization (clitoromegaly, 
deepening of the voice, frontal balding and muscle hypertrophy) (Table 2)22. It is suggested 
that such tumours could be identified based on clinical (rapid onset of symptoms and 
virilization), and biochemical features (extremely high androgen levels), whilst cases of 
slowly evolving tumours exhibiting a wide range of elevated androgen levels can occur3,23,24. 
It has been suggested that only testosterone levels >5 nmol/L are highly suggestive of 
androgen-secreting tumours23,24. The most common virilising ovarian tumour is 
arrhenoblastoma, which can occasionally be gonadotrophin dependent3,22. Adrenal 
androgen producing tumours are usually malignant, although benign tumours have also 
been reported3,22,25. Malignant adrenal tumours characteristically produce androgens 
(mainly testosterone and DHEA-S) and/or cortisol resulting in a mixed phenotype; however, 
approximately 10% can present solely with virilization3,22. Prompt diagnosis and treatment 
of these tumours, particularly adrenal carcinomas, is important as disease stage at diagnosis 
correlates with survival3,22.          
 
The use of some medications may be associated with hyperandrogenism and menstrual 
irregularity. Although exogenous androgen administration was thought to induce 
PCO/PCOS, this has been proven only when supra-physiological doses are given (as in cases 
of female-to-male transsexuals)26 . Valproic acid was initially considered to induce PCOS, but 
this was not substantiated by further studies, whereas drugs producing hirsutism have not 
been shown to induce PCO/PCOS3.   
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Other rarer causes exhibiting a PCOS-phenotype    
Relatively rare disorders that exhibit distinctive clinical and/or endocrinological features can 
also present with a PCOS-like phenotype. In the HAIR-AN syndrome [hyperandrogenism 
(HA), IR and acanthosis nigricans (AN)] the degree of IR and subsequent hyperinsulinemia 
lead to increased ovarian androgen production27. Such patients usually present from 
puberty and have variable levels of hyperandrogenism27. In addition, in a number of 
common disorders associated with hyperinsulinemia and IR, such as type 2 diabetes 
mellitus, gestational diabetes and obesity, the prevalence of PCO/PCOS is substantially 
increased, but this is anticipated due to the underlying disorder3.     
Glucocorticoid resistance (GR) or altered cortisol metabolism states can also lead to the 
development of a PCOS-phenotype albeit being extremely rare28,29. In the former, 
compensatory ACTH rise leads to excessive adrenal androgen production and development 
of hirsutism, menstrual irregularity and infertility mimicking PCOS28. Elevated cortisol and 
ACTH levels that maintain normal circadian rhythm and absence of a CS-phenotype are the 
hallmarks for making a proper diagnosis28. Enzymatic defects, such as overactivity of 5α-
reductase that converts testosterone to the more potent dihydro-testosterone, as well as 
deficiency of 11-oxoreductase that converts cortisone to cortisol, are associated with 
enhanced cortisol metabolism, ACTH hypersecretion and subsequent hyperandrogenism.  
However, both these conditions are extremely rare causes of PCOS3,29.     
 
Conclusions 
Most women with hyperandrogenism and chronic anovulation will be found to have PCOS. 
However, as these findings are not specific to PCOS the number of disorders that needs to 
be excluded should be expanded. Early onset and low grade states of cortisol or GH excess 
along with evolving androgen secreting tumours should be considered and promptly 
investigated in the presence of relevant clinical/endocrine settings. Conditions associated 
with severe insulin resistance also need to be considered as they can frequently be 
associated with a PCOS-phenotype (Figure 1). 
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Legends 
 
Table 1. Current criteria for diagnosing PCOS 
Table 2. Features of tumours associated with hyperandrogenemia 
Figure 1¶. Diagnostic algorithm for the identification of PCOS mimicking conditions.  
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Table 1. Current criteria for diagnosing PCOS 
 
 NIH 
criteria 
Rotterdam 
criteria 
Androgen 
excess Society 
criteria 
Hyperandrogenism  Clinical: hirsutism, acne, androgenic alopecia 
Biochemical: increased total, bioavailable or 
free testosterone levels 
+ + + 
 
Oligo/anovulation  Bleeding intervals of < 21 (polymenorrhea) or > 
35 days (oligo- or amenorrhea) 
+  
 
 
+ + 
 
Exclusion of other 
diagnoses 
Thyroid disease 
Non-classic congenital adrenal hyperplasia 
Hyperprolactinaemia 
+ + + 
 
PCO morphology 12 or more 2-9mm in diameter follicles and/or 
ovarian volume > 10 ml in either ovary 
 
 
 
+ + 
 
 
 
All criteria require exclusion of other diagnoses with a PCO-like phenotype. Rotterdam require any 2 of 
remaining 3 criteria, Androgen Excess Society requires hyperandrogenism with 1 of the remaining 2 criteria, 
whereas NIH do not include PCO morphology. (PCO= polycystic ovarian) 
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Table 2: Features of tumours associated with hyperandrogenemia 
Tumour Age at presentation 
(range, years) 
Incidence in relevant 
tumour entity (%) 
Hormone secretion Symptoms Bilaterality Malignant potential 
Adrenal tumours 
Adrenal carcinoma 
Adrenal adenoma 
 
3-79 
Variable 
 
 
4-5% 
<1% 
 
Testosterone, DHEA-S, 
Androstenedione 
 
CS 
Virilization 
 
Unilateral 
 
High 
Very low 
Ovarian tumours 
Androblastoma (Sertoli-Leydig cell tumours) 
Granulosa cell tumours 
Sertoli cell tumours 
Hillus cell tumour 
 
2-75 
40-70 
7-79 
6th decade 
 
0.5 
2-3 
0.1 
0.02 
 
Androgen, rarely estrogens 
Estrogens, rarely androgens 
Androgens rarely estrogens 
Androgens 
 
 
Virilization 1/3 
Rarely virilization 
Virilization in 30% 
Hirsutism and virilization 50-
75% 
 
1-2% 
5% 
1-2% 
Rare 
 
Low 
Low 
Low 
Very rare 
Other type of tumours 
NET (pNET) tumour30 
 
 
Can be variable 
 
<0.1% 
 
LH 
 
Hirsutism, menstrual 
irregularity 
 
Extra- 
adrenal 
 
Intermediate 
 
DHEA-S= dehydroepiandrosterone sulfate; CS= Cushing’s syndrome; NET= neuroendocrine tumour; pNET= pancreatic neuroendocrine tumour 
 
Figure 1¶. Diagnostic algorithm for the identification of PCOS mimicking  conditions. 
17OH-PG= 17-hydroxyprogesterone; Δ4-Α= Δ4-androstenedione; DHEA-S= dehydroepiandrosterone 
sulfate; U/S = ultrasound; UFC= urinary free cortisol;  LDDST = Low-dose dexamethasone suppression 
test (0.5 mg every 6 h for 48 h); OGTT= oral glucose tolerance test (75 gr glucose per os) ; NC-CAH = 
nonclassic (late-onset) congenital adrenal hypeplasia; CS= Cushing’s syndrome; PCO= polycystic 
ovaries; PCOS= polycystic ovarian syndrome; CT= computed tomography; MRI= magnetic resonance 
imaging.
*Testosterone response to LDDST is defined as 40% decrease or normalization of serum 
testosterone following LDDST. 
**GnRH analog administration has been shown to suppress the gonadotrophins leading to 
normalization of elevated testosterone levels in patients with ovarian androgen-secreting tumours, 
as well as hyperthecosis, although it cannot assist in the differential diagnosis between the two 
conditions.
¶ Amended from Reference 22
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